... Abstract The possibility of genetically engineering poultry to make them resistant to avian influenza is attracting attention and has now become a real possibility with improved methods for genetic modification and the emergence of RNAi as an antiviral strategy. In order to test...

... interference (RNAi), one type of posttranscriptional gene silencing, as anovel gene therapeutic possibility and describe the mechanism and kinetics of action. Wehighlight the correlation between structure and efficacy of small interfering and short hairpinRNAs that are the most often used small RNAs possessing...

... Abstract Targeting and downregulating specific genes with antisense and decoy oligonucleotides, ribozymes or RNA interference (RNAi) offer the theoretical potential of altering a disease phenotype. Here we review the molecular mechanism behind the in vivo application of RNAi-mediated gene...

... by Inhibitory RNA A therapeutic vision is to convert a severe OI type to a type I OI by silencing the mutated gene. One possible approach would be to use gene silencing through RNAi. The attractiveness of RNAi in contrast to other molecular methods arises from its high inhibitory activity and the fact...

...- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494 18. Zimmermann TS, Lee AC, Akinc A, et al: RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111 19. Dykxhoorn DM, Schlehuber LD, London I M, Lieberman J: Determinants of specific RNA...

... development, one can see that the “modulation of gene expression” as a conceptual term was prohibited in the second version (Table 1 ). This term has been removed, since it would basically include almost all conventional doping substances along with the techniques of RNA interference (RNAi) using the siRNAs...

... that specifically target this GH isoform may be useful to treat IGHD-2 patients with splicing mutations while avoiding the side-effects of long-term post-pubertal exogenous GH therapy. IGHD-2:Therapeutic Approaches by RNA Interference Rescue of IGHD-2 in vitro and in vivo by RNAi In the last decade, few...

... of genetic networks via tissue-specific transduction and RNAi in mouse embryos. Nat Med 2010;16:821-827 19. Williams SE, Beronja S, Pasolli HA, Fuchs E: Asymmetric cell divisions promote Notch-dependent epidermal differentiation. Nature 2011;470:353-358 20. Ezratty EJ, Stokes N, Chai S, Shah...

... in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007;6:1478-1482 32. Pai SI, Lin Y-Y, Macaes B, Meneshian A, Hung CF, Wu TC: Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-477 33. Maen A, Stephen S, Cheryl B, Ala A: RNAi and cancer: implications and applications. J RNAi...

... in neurodegenerative diseases. Science 2012;336:1511-1513. 4. Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science 2008;319:916-919. 5. Coelho T, Adams D, Silva A, Lozeron P, et al: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med...

.... Quintana RM, Dupuy AJ, Bravo A, et al: A transposon-based analysis of gene mutations related to skin cancer development. J Invest Dermatol 2013;133:239-248. 33. Beronja S, Janki P, Heller E, et al: RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 2013;501:185-190...

... and/or outside the cell. The latter maladies, often associated with aging, include notably PD and AD. RNA RNA interference (RNAi)-based proteostasis regulators that readjust disaggregase and chaperone levels through manipulation of aging signaling pathways substantially delay the onset of the gain of toxicity...

...References References 1. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human MicroRNA targets. PLoS Biol 2004;2:e363. 2. Murchison EP, Hannon GJ: miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 2004;16:223-229. 3. Kato M, Zhang J, Wang M...

... PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH: Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 2013;5(209):ra152. 39. Liu Z, Tabakman SM, Chen Z, Dai H: Preparation of carbon nanotube bioconjugates...

... (RNAi) of NFAT3; furthermore, in response to UV radiation, activation of the TNF reporter is strongly inhibited by mutation of the -180 and -76-NFAT sites, and NFAT3 is recruited to the endogenous TNF promoter [ 68 ]. RNAi of NFAT3 also inhibited TNF transcription in a murine epidermal cell line...

... interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 2007;35:5154-5164 37. Naldini L: Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998;9:457-463 38. Marquis J, Kampfer SS, Angehrn L, Schumperli D: Doxycycline...

... gene expression experiments. More than 250 experiments related to differentially expressed GH genes are currently archived in the gene expression atlas with links and analysis for organ, disease, cell lines, compound treatment and RNAi experiments. The DMDM gateway page for human GH showing mapping...

... the function of SMOC1 is at present unclear, this glycoprotein belongs to the SPARC matricellular protein family believed to mediate cell-extracellular matrix interactions, and studies in Xenopus indicate that SMOC1 functions as a BMP antagonist [ 86 ]. The discovery of RNA interference (RNAi) elicited...